WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Functional polymorphisms on the VEGF-A gene, known to be linked to cancer risk or to VEGF-A plasma concentrations, have been identified. So far, limited knowledge has been published on the relationships between toxicity/efficacy of bevacizumab-based therapy and VEGF-A polymorphisms (tumoral DNA). We therefore prospectively tested the impact of these five gene polymorphisms (blood DNA) on the pharmacodynamics of bevacizumab-based treatment administered in metastatic breast cancer patients. WHAT THIS STUDY ADDS: • Present data obtained from a prospective study suggest a role for VEGF-A 936C > T polymorphism as a potential predictor of time to progression in breast cancer patients receiving bevacizumab-containing therapy. Also, the VEGF-A-634G > C polymorphism was linked to bevacizumab-related toxicity. AIMS To test prospectively the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-chemotherapy in breast cancer patients. METHODS: As part of the single-arm MO19391 trial, 137 women with locally recurrent or metastatic breast cancer receiving first-line bevacizumab-containing therapy were analysed. Patients received bevacizumab associated (76%) or not (24%) with taxane-based chemotherapy. Clinical evaluation included clinical response, time to progression (TTP) and a toxicity score corresponding to the sum of each maximum observed toxicity grade (hypertension, haemorrhage, arterial and venous thrombo-embolism). Functional VEGF-A polymorphisms at position -2578 C > A, -1498 T > C, -1154 G > A, -634 G > C and 936 C > T were analysed by PCR-RFLP (blood DNA). RESULTS: Overall response rate (complete response (CR) + partial response (PR)) was 61%. Median TTP was 11 months. None of the VEGF-A polymorphisms was significantly linked to clinical response. Analysis of the 936C > T polymorphism revealed that the 96 patients homozygous for the 936C allele exhibited a marked tendency for a shorter TTP (median 9.7 months) than the 32 patients bearing the 936T allele (median 11.5 months, P= 0.022) of which 30 were CT and two were homozygous TT. Other polymorphisms did not influence TTP. VEGF-A-634 G > C was significantly related to the toxicity score with 39%, 49% and 81% of patients with score >1 in GG, GC and CC patients, respectively (P= 0.01). CONCLUSIONS: The role for VEGF-A 936C > T polymorphism as a potential marker of TTP in breast cancer patients receiving bevacizumab-containing therapy concords with the known impact of VEGF-A 936C > T polymorphism on VEGF-A expression.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Functional polymorphisms on the VEGF-A gene, known to be linked to cancer risk or to VEGF-A plasma concentrations, have been identified. So far, limited knowledge has been published on the relationships between toxicity/efficacy of bevacizumab-based therapy and VEGF-A polymorphisms (tumoral DNA). We therefore prospectively tested the impact of these five gene polymorphisms (blood DNA) on the pharmacodynamics of bevacizumab-based treatment administered in metastatic breast cancerpatients. WHAT THIS STUDY ADDS: • Present data obtained from a prospective study suggest a role for VEGF-A 936C > T polymorphism as a potential predictor of time to progression in breast cancerpatients receiving bevacizumab-containing therapy. Also, the VEGF-A-634G > C polymorphism was linked to bevacizumab-related toxicity. AIMS To test prospectively the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-chemotherapy in breast cancerpatients. METHODS: As part of the single-arm MO19391 trial, 137 women with locally recurrent or metastatic breast cancer receiving first-line bevacizumab-containing therapy were analysed. Patients received bevacizumab associated (76%) or not (24%) with taxane-based chemotherapy. Clinical evaluation included clinical response, time to progression (TTP) and a toxicity score corresponding to the sum of each maximum observed toxicity grade (hypertension, haemorrhage, arterial and venous thrombo-embolism). Functional VEGF-A polymorphisms at position -2578 C > A, -1498 T > C, -1154 G > A, -634 G > C and 936 C > T were analysed by PCR-RFLP (blood DNA). RESULTS: Overall response rate (complete response (CR) + partial response (PR)) was 61%. Median TTP was 11 months. None of the VEGF-A polymorphisms was significantly linked to clinical response. Analysis of the 936C > T polymorphism revealed that the 96 patients homozygous for the 936C allele exhibited a marked tendency for a shorter TTP (median 9.7 months) than the 32 patients bearing the 936T allele (median 11.5 months, P= 0.022) of which 30 were CT and two were homozygous TT. Other polymorphisms did not influence TTP. VEGF-A-634 G > C was significantly related to the toxicity score with 39%, 49% and 81% of patients with score >1 in GG, GC and CC patients, respectively (P= 0.01). CONCLUSIONS: The role for VEGF-A 936C > T polymorphism as a potential marker of TTP in breast cancerpatients receiving bevacizumab-containing therapy concords with the known impact of VEGF-A 936C > T polymorphism on VEGF-A expression.
Authors: L G Presta; H Chen; S J O'Connor; V Chisholm; Y G Meng; L Krummen; M Winkler; N Ferrara Journal: Cancer Res Date: 1997-10-15 Impact factor: 12.701
Authors: F-C Bidard; C Mathiot; A Degeorges; M-C Etienne-Grimaldi; R Delva; X Pivot; C Veyret; L Bergougnoux; P de Cremoux; G Milano; J-Y Pierga Journal: Ann Oncol Date: 2010-03-16 Impact factor: 32.976
Authors: G Gasparini; M Toi; M Gion; P Verderio; R Dittadi; M Hanatani; I Matsubara; O Vinante; E Bonoldi; P Boracchi; C Gatti; H Suzuki; T Tominaga Journal: J Natl Cancer Inst Date: 1997-01-15 Impact factor: 13.506
Authors: Angelos K Koutras; George Fountzilas; Thomas Makatsoris; Stavros Peroukides; Haralabos P Kalofonos Journal: Cancer Treat Rev Date: 2009-11-22 Impact factor: 12.111
Authors: Harold J Burstein; Yu-Hui Chen; Leroy M Parker; Jennifer Savoie; Jerry Younger; Irene Kuter; Paula D Ryan; Judy E Garber; Helen Chen; Susana M Campos; Lawrence N Shulman; Lyndsay N Harris; Rebecca Gelman; Eric P Winer Journal: Clin Cancer Res Date: 2008-12-01 Impact factor: 12.531
Authors: Lokesh Jain; Craig A Vargo; Romano Danesi; Tristan M Sissung; Douglas K Price; David Venzon; Jürgen Venitz; William D Figg Journal: Mol Cancer Ther Date: 2009-09-15 Impact factor: 6.261
Authors: Michael I Koukourakis; Dimitrios Papazoglou; Alexandra Giatromanolaki; George Bougioukas; Efstratios Maltezos; Efthimios Sivridis; Efthimios Siviridis Journal: Lung Cancer Date: 2004-12 Impact factor: 5.705
Authors: Megan Li; Flora Mulkey; Chen Jiang; Bert H O'Neil; Bryan P Schneider; Fei Shen; Paula N Friedman; Yukihide Momozawa; Michiaki Kubo; Donna Niedzwiecki; Howard S Hochster; Heinz-Josef Lenz; James N Atkins; Hope S Rugo; Susan Halabi; William Kevin Kelly; Howard L McLeod; Federico Innocenti; Mark J Ratain; Alan P Venook; Kouros Owzar; Deanna L Kroetz Journal: Clin Cancer Res Date: 2018-06-05 Impact factor: 12.531
Authors: S P Gampenrieder; C Hufnagl; S Brechelmacher; F Huemer; H Hackl; G Rinnerthaler; F Romeder; C Monzo Fuentes; P Morre; C Hauser-Kronberger; B Mlineritsch; R Greil Journal: Pharmacogenomics J Date: 2016-05-03 Impact factor: 3.550
Authors: Meng Zhao; Xueliang Pan; Rachel Layman; Maryam B Lustberg; Ewa Mrozek; Erin R Macrae; Robert Wesolowski; Sarah Carothers; Shannon Puhalla; Charles L Shapiro; Bhuvaneswari Ramaswamy Journal: Invest New Drugs Date: 2014-06-05 Impact factor: 3.850